GlassScriptPhysician profile
Shawn Ragbir
NPI 1831350990
$2,980.57
in general payments reported to CMS, 2019-2025
20 companies · $601 in 2025
The $601 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $115 · 2021: $209 · 2022: $206 · 2023: $888 · 2024: $697 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,186.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $835.52 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $572.34 | 2021-2024 | Xarelto |
| Amgen INC. | $270.53 | 2023-2025 | Repatha, Evenity, Repatha |
| Pfizer INC. | $228.93 | 2022-2024 | |
| Shockwave Medical, INC | $151.83 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Globus Medical, INC. | $132.82 | 2025 | Senza |
| Phathom Pharmaceuticals, INC. | $124.99 | 2024 | Voquezna |
| Intuity Medical INC | $115.74 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.77 | 2020-2023 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $78.60 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $68.10 | 2025 | Verquvo, Capvaxive |
| Esperion Therapeutics, INC. | $53.06 | 2022-2025 | Nexletol |
| Cvrx, INC. | $50.97 | 2025 | Barostim Neo System |
| Boston Scientific Corporation | $49.82 | 2025 | Cds - Mct/Cem Monitoring |
| Astrazeneca Pharmaceuticals LP | $48.76 | 2023 | Farxiga |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $45.31 | 2024 | |
| Abbott Laboratories | $22.16 | 2025 | Jot Dx |
| Bayer Healthcare Pharmaceuticals INC. | $17.47 | 2025 | |
| Glaxosmithkline, LLC. | $16.90 | 2025 | Arexvy, Shingrix |
| Tactile Systems Technology INC | $15.95 | 2025 | Flexitouch Plus, Nimbl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Ragbir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.